DCTH Margin dodolan operasi Delcath Systems Inc

Logo perusahaan publik Delcath Systems, Inc. (DCTH)

Rising sales of the Hepzato system for melanoma treatment are accelerating revenue for Delcath Systems, Inc. (DCTH), driving active momentum in the operating profit margin, which currently stands at approximately 5.20. The business model is based on capturing the liver metastasis targeted therapy niche with high-margin consumables. Structural flexibility is maintained through the complete outsourcing of production and clinical trials to external partners.

DCTH: Tingkat bathi operasi Delcath Systems Inc 04.07.2022 - 19.11.2026

DCTH (Delcath Systems): rincian analitis lan laporan miturut indikator

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:DCTH, Delcath Corp
Barang utama delcath.com

The metric is calculated as the ratio of operating profit to total revenue. This metric determines cost management efficiency before accounting for financial leverage and tax obligations. For Delcath Systems, Inc. (DCTH), it reflects the oncology team's ability to monetize innovations in medical devices. The efficiency of clinical trials directly impacts the operating result. By analyzing the operating profit margin, an investor assesses the real profitability of the core business.

Analisis pesaing

Rentabilitas operasi BeiGene Ltd|Halozyme Therapeutics - Margin bathi operasi|Margin dodolan operasi RVMD (Revolution Medicines Corp)|Rasio bathi operasi AAPG|Rentabilitas operasi CG Oncology Therapeutics CGON|Tingkat bathi operasi URGN|BCAX: Margin dodolan operasi|PSNL: Rentabilitas operasi|Erasca (ERAS) - Rentabilitas operasi|Y-mAbs Therapeutics - Tingkat bathi operasi|AURA (Aura Biosciences Inc) - Margin operasi|Rentabilitas dodolan operasi candeltx.com CADL|Margin operasi ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Tingkat bathi operasi|Rentabilitas operasi Actuate Therapeutics, Inc. ACTU|citiusonc.com - Rentabilitas operasi|TuHURA Biosciences Inc. - Margin operasi|TARA - Margin operasi|FATE (Fate Therapeutics) - Margin dodolan operasi|Margin dodolan operasi Aadi Bioscience, Inc.|Margin dodolan operasi TCRX|Rentabilitas operasi CSBR|Margin operasi XBIT|Rentabilitas kegiatan operasi CEL-SCI Corp.|Rentabilitas operasi ostherapies.com OSTX|RADX: Rentabilitas dodolan miturut bathi operasi|ARTV: Margin dodolan operasi|ANL (Adlai Nortye) - Rentabilitas dodolan miturut bathi operasi|Veru (VERU) - Rentabilitas operasi|Margin dodolan operasi Tempest Therapeutics Inc|Rentabilitas operasi Xilio Therapeutics|Rentabilitas dodolan miturut bathi operasi RENB (Renovaro Inc.)|Rentabilitas operasi Mural Oncology PLC (MURA)|Margin operasi Kairos Pharma (KAPA)|Rentabilitas operasi onkuretherapeutics.com OKUR|GDTC: Rentabilitas dodolan miturut bathi operasi|CRIS: Margin dodolan operasi|apollomicsinc.com (APLM) - Margin dodolan operasi|THAR: Margin operasi|Margin dodolan operasi Advanced Biomed Inc.|Margin dodolan operasi GNPX|Rentabilitas dodolan miturut bathi operasi CLDI (Calidi Biotherapeutics)|Margin operasi SBFM|Xenetic Biosciences, Inc. - Rentabilitas dodolan miturut bathi operasi|Rentabilitas operasi Salarius Pharmaceuticals SLRX|Margin operasi purple-biotech.com PPBT|AONC - Rentabilitas operasi|BGNE: Rentabilitas operasi|CKPT: Margin operasi|Elevation Oncology - Tingkat bathi operasi|ICAD (iCAD) - Margin operasi|IKNA: Tingkat bathi operasi|Rentabilitas operasi Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Tingkat bathi operasi|Rentabilitas operasi MorphoSys Corporation MOR|NAYA: Rentabilitas dodolan miturut bathi operasi|Ascentage Pharma Group International - Margin operasi